- Report
- June 2019
- 71 Pages
Global
€2702EUR$2,950USD£2,297GBP
- Report
- May 2024
- 131 Pages
Global
From €5953EUR$6,499USD£5,060GBP
- Report
- May 2024
- 137 Pages
Global
From €5953EUR$6,499USD£5,060GBP
- Report
- May 2024
- 135 Pages
Global
From €5953EUR$6,499USD£5,060GBP
- Report
- November 2023
- 150 Pages
Global
From €4443EUR$4,850USD£3,776GBP
- Report
- May 2023
- 118 Pages
Global
From €4122EUR$4,500USD£3,504GBP
- Report
- August 2022
- 138 Pages
Global
From €4122EUR$4,500USD£3,504GBP
- Report
- December 2023
- 143 Pages
Global
From €4076EUR$4,450USD£3,465GBP
- Report
- January 2025
- 80 Pages
India
From €3206EUR$3,500USD£2,725GBP
- Report
- September 2024
- 82 Pages
Japan
From €3206EUR$3,500USD£2,725GBP
- Report
- August 2024
- 80 Pages
Japan
From €3206EUR$3,500USD£2,725GBP
- Report
- August 2023
- 117 Pages
Global
From €4122EUR$4,500USD£3,504GBP
- Report
- February 2024
- 120 Pages
Global
From €4351EUR$4,750USD£3,698GBP
- Report
- August 2022
- 116 Pages
Global
From €4351EUR$4,750USD£3,698GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4534EUR$4,950USD£3,854GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4534EUR$4,950USD£3,854GBP
- Report
- February 2024
- 115 Pages
Global
From €4351EUR$4,750USD£3,698GBP
- Report
- April 2023
- 111 Pages
Global
From €4351EUR$4,750USD£3,698GBP
- Report
- January 2024
- 200 Pages
Global
From €3802EUR$4,150USD£3,231GBP
- Report
- August 2023
- 145 Pages
Global
From €2886EUR$3,150USD£2,452GBP

Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. People with hemophilia lack certain proteins, called clotting factors, which are necessary for normal blood clotting. Without these clotting factors, even a minor injury can cause excessive bleeding. Hemophilia is classified into two main types, hemophilia A and hemophilia B, depending on the clotting factor that is missing.
The hemophilia market is a subset of the hematology market, which includes treatments for a variety of blood-related disorders. The hemophilia market is composed of treatments for hemophilia A and B, such as recombinant clotting factors, gene therapy, and other treatments. These treatments are used to reduce the frequency and severity of bleeding episodes, as well as to prevent bleeding in the first place.
Some companies in the hemophilia market include Novo Nordisk, Pfizer, Shire, Bayer, and CSL Behring. Show Less Read more